Adding Patiromer Allows More Spironolactone in Resistant HTN, CKD Adding Patiromer Allows More Spironolactone in Resistant HTN, CKD

With or without heart failure, add-on treatment with the potassium sequestrant ' enabled ' more intensive use of the aldosterone blocker otherwise limited by hyperkalemia, according to the AMBER trial.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Cardiology News Source Type: news